Group 1: Company Overview - Brother Technology Co., Ltd. has been engaged in the fine chemical industry for over 30 years, expanding its business segments to include vitamins, flavors and fragrances, chromium salts, and pharmaceuticals since its listing in 2011 [1] - The company operates four production bases located in Haining, Yancheng, Jiujiang, and South Africa [1] - The strategic positioning of the company is as a professional health product service provider, focusing on animal nutrition and human health [1] Group 2: Financial Performance - In 2024, the company achieved a turnaround in net profit, primarily due to increased prices and sales volumes of Vitamin B1, along with reduced inventory costs and lower product costs [2] - The first quarter of 2025 saw a year-on-year turnaround with a 152.68% increase, driven by higher sales prices of Vitamin B1 [2] Group 3: Product Applications and Market - The downstream applications of phenol include food, daily chemicals, pesticides, pharmaceuticals, dyes, and polymer materials, with its use in producing flavors and fragrances, antioxidants, and intermediates [3] - The company's phenol products are now officially sold in the PEEK sector, following long-term process optimization and customer validation [4] Group 4: Production Capacity and Utilization - The company currently has a production capacity of 20,000 tons for phenol and para-phenol, with plans to further enhance capacity through the second phase of the phenol project in 2025 [5] - In 2024, the overall capacity utilization rate improved significantly, with the pharmaceutical and food sector achieving 89.66% and the specialty chemicals sector reaching 95.30% [7] Group 5: Sales and Trade Impact - In 2024, overseas sales accounted for 56.11% of total sales, with the majority of exports to the U.S. being vitamin products, which are exempt from additional tariffs [6] Group 6: Future Plans - The company aims to strengthen its competitive advantage through technological innovation, extending the industrial chain, cost reduction, and timely capacity expansion [8] - The refinancing project has passed the Shenzhen Stock Exchange review and is currently in the registration phase with the regulatory authority [9]

Core Viewpoint - PEEK (Polyether Ether Ketone) is a third-generation high-performance thermoplastic engineering plastic that excels in heat resistance, wear resistance, and corrosion resistance, making it an ideal substitute for metals and ceramics in various demanding applications [2][8]. Group 1: Performance Characteristics - PEEK exhibits outstanding properties such as high temperature resistance (long-term use temperature > 260 °C), self-lubrication (friction coefficient 0.15–0.35), high strength (tensile strength > 150 MPa), and chemical stability (resistant to pH 1–14 corrosion) [2][13]. - Compared to traditional materials, PEEK's comprehensive performance and high product added value position it as a leading choice in specialized engineering plastics [10][14]. Group 2: Synthesis Process - The primary method for synthesizing PEEK is nucleophilic substitution, which allows for precise control over the reaction process, resulting in high purity and structural integrity of the material [3][19]. - The synthesis process requires stringent conditions and high-quality raw materials, leading to higher production costs [22][26]. Group 3: Demand and Applications - PEEK is widely used in various industries, including aerospace, automotive, electronics, and medical fields, due to its lightweight and high-performance characteristics [4][34]. - The demand for PEEK is expected to grow significantly, particularly in robotics, where the estimated demand could reach 10,000 tons, corresponding to a market size of 4 billion yuan if production reaches one million units [4][34]. Group 4: Supply and Market Dynamics - The global PEEK market is dominated by a few key players, including Victrex, Solvay, and Evonik, while domestic companies like Zhongyan Co., Watte Co., and Jinfat Co. are rapidly increasing their production capacity [5][6]. - The supply chain for PEEK's raw materials, such as DFBP and phenol, is primarily concentrated in China, with limited global production capacity [5][24]. Group 5: Future Outlook - The domestic PEEK market is projected to reach 5,078.98 tons by 2027, excluding the robotics sector, indicating a robust growth trajectory [6]. - Innovations in material modification technologies and processing methods, such as 3D printing, are expected to further expand PEEK's applications in various fields [4][34].

上海市广发律师事务所 关于兄弟科技股份有限公司 2024 年度股东大会的 2024 年度股东大会的法律意见书 致：兄弟科技股份有限公司 兄弟科技股份有限公司（以下简称"公司"）2024 年度股东大会于 2025 年 5 月 21 日在浙江省海宁市海洲街道学林街 1 号兄弟科技股份有限公司会议室召 开。上海市广发律师事务所经公司聘请，委派孙薇维律师、成赟律师出席现场会 议。根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股东会规则》（以下简称"《股东会规则》"）等法律法规、其他规范性文件以 及《兄弟科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本 次股东大会的召集和召开程序、召集人及出席会议人员的资格、会议议案、表决 方式和表决程序、表决结果和会议决议等出具本法律意见书。 法律意见书 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 公司已向本所保证和承诺，公司向本所律师所提供的文件和所作的陈述和说 明是完整的、真实的和有效的，有关原件及其上面的签字和印章是真实的，且一 切足以影响本法律意见书的事实 ...

证券代码：002562 证券简称：兄弟科技 公告编号：2025-038 兄弟科技股份有限公司 关于 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有增加、否决或变更提案的情况。 2、本次股东大会采取现场投票与网络投票相结合的表决方式。 3、本次股东大会不涉及修改前次股东大会决议。 一、会议召开情况 1、会议召开时间： （1）现场召开时间为：2025 年 5 月 21 日下午 14:00； （2）网络投票时间为： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 21 日上午 9:15- 9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年5月21日9:15-15:00 期 间的任意时间。 2、现场会议地点：浙江省海宁市海洲街道学林街1号 兄弟科技股份有限公司会议室 3、会议方式：现场会议表决与网络投票相结合的方式 4、会议召集人：公司董事会 5、会议主持人：董事长钱志达先生 会议的召集、召开与表决程序符 ...

Group 1: Company Performance and Financials - In Q1 2025, the company achieved a revenue of 91,889.17 million, representing a year-on-year growth of 12.10% [2] - The net profit for Q1 2025 was 2,090.81 million, showing a significant year-on-year increase of 182.95% [2] Group 2: Production Capacity and Products - The company currently has a production capacity of 20,000 tons for phenol and para-phenol, with the second phase of the phenol project expected to be operational in the first half of 2024 [1][2] - The phenol products are primarily sold to domestic mainstream acrylic acid manufacturers and have entered the PEEK field [2] Group 3: Stock Performance and Management - The company’s stock price is influenced by multiple factors, and management is committed to improving operations to provide good returns to shareholders [1][2] - The controlling shareholder has announced a reduction in holdings, which has raised concerns among investors [2][3] Group 4: Strategic Development - The company plans to expand its existing industries, including vitamins, flavors, pharmaceuticals, and chromium salts, through investments, mergers, and technological innovations [2] - The company is actively promoting its iodinated contrast agents after obtaining the necessary domestic registration approvals [3]

Core Viewpoint - Brother Technology Co., Ltd. is planning to issue A-shares to specific investors to raise funds primarily for expanding its production capacity of iodinated contrast agents, with a focus on addressing market demand and potential risks associated with capacity utilization and economic performance [1][2][3]. Group 1: Company Overview - Brother Technology Co., Ltd. was established on March 19, 2001, with a registered capital of 1,063.70 million RMB [14]. - The company operates in the pharmaceutical and specialty chemicals sectors, focusing on the production of iodinated contrast agents and other related products [14]. - The company is headquartered in Haining, Zhejiang Province, China, and is listed on the Shenzhen Stock Exchange under the stock code 002562 [14]. Group 2: Fundraising and Investment Plans - The company plans to raise up to 4,367.50 million RMB through the issuance of A-shares, with the funds allocated primarily for a project to produce 1,150 tons of iodinated contrast agents, including 600 tons of iodinated contrast agent raw materials [9][10]. - The total investment for the iodinated contrast agent project is estimated at 6,901.86 million RMB, with 5,600.00 million RMB of the raised funds designated for this project [10]. - The company has conducted feasibility studies and market analysis to ensure the viability of the investment projects [1][2]. Group 3: Risks and Challenges - The company faces risks related to the absorption of new production capacity, as the expansion from 100 tons to 700 tons of iodinated contrast agent raw materials may lead to overcapacity if market demand does not meet expectations [1][2]. - There are concerns regarding the economic performance of previous fundraising projects, particularly the "Phenol Phase II Project," which may not achieve the anticipated economic benefits [2][3]. - The company is also exposed to industry cyclicality, price fluctuations of raw materials, and regulatory uncertainties that could impact its operational performance and profitability [4][5][6].

股票简称：兄弟科技 股票代码：002562 兄弟科技股份有限公司 （住所：浙江省海宁市周王庙镇联民村蔡家石桥 3 号） 2023 年度向特定对象发行 A 股股票 募集说明书 （注册稿） 保荐机构（主承销商） （住所：中国（上海）自由贸易试验区商城路 618 号） 二〇二五年五月 兄弟科技股份有限公司 2023 年度向特定对象发行 A 股股票募集说明书 声 明 本公司全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假、误导性陈述或重大遗漏，并保证所披露信息的真实、准 确、完整。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保 证募集说明书中财务会计报告真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与 之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收 ...

兄弟科技股份有限公司 关于向特定对象发行股票的募集说明书（注册稿）等 申请文件更新的提示性公告 股票代码：002562 股票简称：兄弟科技 公告编号：2025-037 公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者谨慎决策，注意 投资风险。 特此公告。 兄弟科技股份有限公司 董事会 2025年5月14日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 兄弟科技股份有限公司（以下简称"公司"）向特定对象发行股票的申请已于2025年4月 11日获得深圳证券交易所上市审核中心审核通过，具体内容详见公司于2025年4月12日在巨潮 资讯网（http://www.cninfo.com.cn）披露的《关于申请向特定对象发行股票获得深圳证券交易 所上市审核中心审核通过的公告》（公告编号：2025-016）。 鉴于公司于2025年4月26日披露了《2024年年度报告》，根据《监管规则适用指引——发 行类第7号》等相关要求，公司会同相关中介机构对募集说明书等申请文件中涉及的财务数据 及其他变动事项进行了同步更新，具体内容详见公司同日在巨潮资讯网披露的相关公告 ...

国泰海通证券股份有限公司 关于 兄弟科技股份有限公司 2023年度向特定对象发行A股股票 之 上市保荐书 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年五月 兄弟科技股份有限公司 上市保荐书 国泰海通证券股份有限公司 关于兄弟科技股份有限公司 2023 年度向特定对象发行 A 股股票 之上市保荐书 深圳证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"或"本保 荐人"）接受兄弟科技股份有限公司（以下简称"兄弟科技"、"公司"或"发 行人"）的委托，担任兄弟科技本次向特定对象发行 A 股股票的保荐人。国泰 海通及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券发行 注册管理办法》（以下简称"《注册管理办法》"）、《证券发行上市保荐业务 管理办法》（以下简称"《保荐管理办法》"）等法律法规和中国证券监督管理 委员会（以下简称"中国证监会"）、深圳证券交易所（以下简称"深交所"） 的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业执业规 范和道德准则出具本上市 ...

国泰海通证券股份有限公司 关于 兄弟科技股份有限公司 2023年度向特定对象发行A股股票 之 发行保荐书 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年五月 发行保荐书 国泰海通证券股份有限公司 关于兄弟科技股份有限公司 2023 年度向特定对象发行 A 股股票之发行保荐书 深圳证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"或"本保 荐人"）接受兄弟科技股份有限公司（以下简称"兄弟科技"、"公司"或"发行 人"）的委托，担任兄弟科技本次向特定对象发行 A 股股票的保荐人。国泰海通 及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券发行注册管理 办法》（以下简称"《注册管理办法》"）、《证券发行上市保荐业务管理办法》（以 下简称"《保荐管理办法》"）等法律法规和中国证券监督管理委员会（以下简称 "中国证监会"）、深圳证券交易所（以下简称"深交所"）的有关规定，诚实守 信，勤勉尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具 本发行保荐书，并保证本发行保荐 ...